100 101

100 2 15

. ............................................ 5
. ............................................ 5
. ............................................ 6
. .......................................... 6
. ............................................ 6
. ............................................ 7
. ............................... 7
. ....................................10
. ............................................12
.

............................13

.........................14

..................................19

......................................21

..................................21

1 ........................................22
2 .......................................25
3

 3 100 101 ..36

4 ............................................40
5 ....................................57
6 ............79
7 .............................88
9 ....................................90
1 .....................................91
2 ...............................117
3-1 .........................118
3-2 ......................118
4 ........119
5

....................124

15

.
71 10
98 39,917
96 75,769
4 10

84 30

92

92 5 21 94
3 10

94-96 20
6 97

 98 10

.
100

30-69 2
110
45-69 1
55
50-69 1
120
30 1
88

101 100

.
100 1 1 100 1 1
101 12 31
6

 2
100 100
101 101 100

.
5 8,500 2 11 7,000
1 3,000 2 2 6,000

101

98 1 1 98 12 31 30
5,000
98 1 1 98 12 31 30
3,000
(: DTLFA
7

)
1

96 450

96 450

99 101

101
2

96 200
2

1. 96 50
class1+2
2
8

2. 96
50 class1+2 50

3.

98 1 2

(: DTLFA)
99 10 25

98

98 1 1 98 12
31 30

98 1 1 98 12
31 30

.
98 1 1 98 12 31 30

5,000 3,000

30
100,000
90,000-99,999
80,000-89,999
70,000-79,999
60,000-69,999
50,000-59,999
40,000-49,999
30,000-39,999
20,000-29,999
10,000-19,999
5,000-9,999
3,000-4,999

10

290
265
240
215
190
165
140
115
90
65
40
30

 98.1.1-98.12.31 30 5
165
96 450

30
320,000
290,000-319,999
260,000-289,999
230,000-259,999
200,000-229,999
170,000-199,999
140,000-169,999
110,000-139,999
80,000-109,999
50,000- 79,999

410
370
330
290
250
210
170
130
90
50

6,000
5,000-5,999
4,000-4,999
3,000-3,999
2,000-2,999
1,000-1,999
450-999

1650
1450
1250
1050
850
650
450

98.1.1-98.12.31 30 14
96 3,000
170 1,050 =1,220
11

96 200

+200
4
+150
3
+100
2

1.

2.
A
98.1.1-98.12.31 30 5 2

165 100 =265

.
5

12


1/5
10
99

180 120 3 5
30
45

.
100 101

100 6
7101
100
1 3,000
1000 500

13

1 1

8 14

.

99 10 7 99 10 25 5

http://www.bhp.doh.gov.tw

https://pfp.bhp.doh.gov.tw 4
14


1. 99

100 101
+

2.
4

10043 102 7

4-6 E-mail
https://pfp.bhp.doh.gov.tw

A4
4 6

1 10

99 10 25
100 101

3
10043
102 7

100 101

15

1.
2.

10

20

20

20

20

100

+ 1
16

1.
2.
3.
40
4.
5.
6.
7.
1.

2. 15

1.
2.
3.
4.
25
5.
6.
7.
8.
9.

1.
2.
15
3.
4.
5.-

5
100

+ 2

1.
2.
17

50

3.
4.
5.
6.
7.

1.
2.
3.
4.
5.
6.
7.

1.
2.

15

25

10

3.
100

1. 75
2.
3.

4

100 101

18

 A4

1.
2.
3.
1
2
3

4
5
4.
5.

.
9

19

101
101

20

.
10043
102 7
022311-27502311-27532311-2760

022311-73002311-7353

21

100 101

10

E-mail
1.
2.
3.
4.

22

1.

2.

(class1+2)

97 40

97 20
60
96 60

(: DTLFA)
99 10 25

1. 98

2. 2
98 1 1 98 12 31
30

23

3. 2

98 1 1 98 12 31 30

4.

24

: 100101

:
:

25

. .....................................................................................
. ..............................................................
. .....................................................................................

....................................................................
............................................................................
........................................................
............................................................................
............................................................................
. .....................................................................................
. ..................................................................................
. ........ .....................................................................................
........................
............................................
...............................................................

..................................................

26

E-mail:

E-mail

27

1.

2.
3.
4.
5.
6.
7.

1.

2.

28

1.
2.
3.
4.
5.
6.
7.
8.
9.

1.
2.

3.
4.
5.-

1.

2.
3.
4.
5.
6.
7.

29

1.
2.
3.
4.
5.
6.
7.

1.
2.

3.

30

31

10

11

12

32

 2
1.

2.

3.

33

34

,(

35

 3 100 101

100 101

10

20

20

20

20

100

100 75

36

100 101

1.

2.
3.
40
4.
5.
6.
7.

1.

15
2.

1.
2.
3.
4.
25
5.
6.
7.
8.
9.

1.
2.

15
3.
4.
5.-

37

100 101

100
100 75

38

100 101

1.

1.
2.
50
3.
4.
5.
6.

15

1.
2.
3.
4.
25
5.
6.
7.

1.
2.
10

3.

100
100 75

39

100

100 12 31

100 101 12 31
100 100
101

3
30%

A4

1.
1

2 100 1 100 1

40

399
iFOBT
(colon C)
(Oral C)

499
99 1-12

2.
1

2 100 1 100 1

399
iFOBT
(colon C)
(Oral C)

499
99 1-12

3.
1

2 100 1 100 1

399
iFOBT
(colon C)
41

(Oral C)

499
99 1-12

100 6 15 1
3 7
50%

A4

3 3
1

100 11 1 7
100 12 10 1
3 20%

A4

3 3
1

42

()

()

()

()

()

43


()

()

()

()

()

()

()

100 11 1

codebook

44

SASSPSS

()

100 11 1
7

()

()

()

()

()

45

()

()

()

()

()

()

46

()

()

4 =
[1-]

2 4

47


94 1 24
94 3 07
96 2 15
97 10 21
98 2 12
98 9 21

101 1 12

103 1
2

48

1.

2.

3.

1.

2.

1.

2.

1.
2.
3.

4.

49

5.
6.

7.

8.
9.

10.

11.

1.
2.
3.

4.

5.
6.

7.

8.
9.
10.

11.

12.

13.
50


14.

15. 3 6
8

16.

17.

18.

19.

20.
21.

22.

1.

2.
3.
4.
5.

51

shareware

52

53

()
()100 101

54

(
)

LOG

55

()
()

()

()

3
() 4

()

()

56

 5
1

1.
2.

1.
2.
1
2
3
4
5
3.
1.
2.

3.
4.

1.

57

2. 30

----
3. 99
X FOBT 1 FOBT
2 3-5 5 36 6 (HPV
) 4

4. 98-101 ()

(1)
(2)HPV DNA testing
(3)
5. 99 8 36 6 HPV
HPV HPV
( HPV ) 6

6.
(1)5813 1517

(2)
(3)

58

7.

1.45-69

2. X
3.
(1) ( 0,4,5 ) 4,5

(2)
(3)

4. ACR X
1

2
5. 99-101

6.
99
X FOBT 1 FOBT
2 3-5 5 36 6 (HPV
59

) 4

1. iFOBT 50-69
1
2
3
2.

1
2 colon B
3

3. iFOBT

1
2 colon C
3 100 3
https://pfp.bhp.doh.gov.tw/
4

a.PEG-ELS phosphosda
b.
c.
60

d.

5 99-101 iFOBT (
)

4.
99

X iFOBT 1 iFOBT
2 3-5 5 36 6 (HPV
)

1.

2 30
ENT

3
2.
1 ENT
5

61

2
3 (basement membrane)
dysplasia

4 WHO dysplasia
5
6 3
oral C
7
3. 1
2 6-15
1 4 1 3
4. 99
X iFOBT 1 iFOBT
2 3-5 5 36 6 (HPV
) 2
4

1.
B C

2. BMI
62

2 1

1. 2
2. 10 12

1. A
A 2

2. 1 A
3.
2 (
)
4. ()
5.

()
1.
63

2.

Class 1~2

4
3. 3 75

98 1 1 6 10

99 1 1

1.

2
5
64

2. 400 0.5

3. 1

4.
1

2
10 Class1~2

3 10 Class1~2
4
5.
6.

1. 10 ()

2.
65

1
2 comorbility
regimens dose

1.

2.
1 99 1 1 AJCC 7 AJCC

FIGO
BCLC Response to Neoadjuvant Therapy
99 1 1
histology(5 ) WHO Name
2

1. 2 1 70%

1
66

2
2
2. 10

6
3

1. AdjuvantNeoadjuvant curative CCRT

2.

1. 17

Ishak modified
67

stagingarchitectural changesfibrosis and cirrhosis Gleasons score Gleasons primary

and secondary patternResponse to Neoadjuvant Therapy

2.
3.

1. 6

()

2.

1.

1 5
2
2.

68

1.

2. 1

3.
1.()

1 ()
2 Port-AHickmenPICC
3 /

4
2.
3. 2

1. DNR
2.

69

3 1
80 20
4 200 1

200

5 1

7 100
ID

1.

2. 50
3. class 1&2 400 1
70

4.
5.
6. 6

1. 1

2.
1

1. -
()
2.
1
71

20
2 6
3
3.
1
2
3
4.
5. ()

6. ()

1. AJCC ()
2 2
2.

3. 3
10%( 99
)
4. 1

72

5. 1

3 2

1. 96 200449 2
3
2. 3
3. 1 A

1.
1
2
3
2.
1
2
3

1. 2

101 99

100
http://w3.nhri.org.tw/nhri_org/tcog/accredit//
73

2.
3.
1
2
4.

5.
6.
7.

1.
2. 50
1
2
3.

1.
2.
3.
4.

74

1.

1
2
3
4
2.

1
2() 70%
3 20%
4 10%

1. (Neoadjuvant
Concurrent Chemoradiotherapy , CCRT
2.
3.
4.

75

1.
2.
3.
4.

5.

1.
1curative intent

2
3
4curative intent
2.()

1()
2(curative intent)

1.

2.

76

1.

1
2

3/
4
2.

3.
1

1.

2.
3.

4.

1. DNR
2.

77

2
3. 100
ID

78

 6
1

1. 30-69 99 11 1 100 10 31 30-69

99 11 1 99 12 31
97 1 1 99 12 31
100 1 1 100 10 31
98 1 1 100 10 31

1. 30
30-69 3

2.
36-69 6 HPV (HPV
)

3. 101

79

1. 99 11 1 100 10 31
HPV
HPV (

) 36-69
6
1
(1) 6 9 200
(2) 9 300
2. 75 50 99
11 1 100 10 31

(
)
2 6
50

2. 45-69
2

3. 50-69

4.

99 11 1 100 10 31 45-69

99 11 1 99 12 31
98 1 1 99 12 31
100 1 1 100 10 31
99 1 1 100 10 31

1.

2. 101

3.
4.

5.

99 11 1 100 10 31
80

1. 4555
50 99 11 1 100 10
31
99
30
2. 5565
50 99 11 1 100 10
31
99
60
3. 65 50
99 11 1 100 10 31

99 100

2
50-69

2 1. 42 45 50

99 11 1 100 10

31
99 11 1 99 12 31
99
99 1 1 99 12 31
70
100 1 1 100 10 2. 4550 50
31 99 1 1 100 10
99 11 1 100 10
31
31
99

130
1. 3. 50 50

99 11 1 100 10 31
2. 101

99

200
3.

4.
iFOBT
5.
Colon C

81

4. 30 99 11 1 100 10 31 30

30 2
2

99 11 1 99 12 31 99

1 1 99 12 31
100 1 1 100 10 31
99 1 1 100 10 31

1. 30

2. 30

3. 101

4.

5.
6.

Oral C
82

1. 4045 50
99 11 1 100 10
31
99
50
2. 4555 50
99 11 1 100 10
31
99
100
3. 55 50 99
11 1 100 10 31

99 160

5. 4

1. 30

1
5000-29999
30000-59999
60000-89999
90000
230

2.
1

2 0

20
10
6

6. 4 1.

20

10
2.
6
1

2 0

1.
7.50-69 1.

99 9 1 100 6 30
6070

50-69
500 550
83

2.

7075
99 9 1 100 10 31
600 650
4
120 3.

75 700

750
1.
2.

A
20

1. 1. 94 1 1 98 12 31 1.
12 5
class 1 class 2
(1) 95%

93 1 1

2.
95%2

123 5
(2)(1)

3. 1
95%1
84

23 5

4. 12
3 5

5.
123 5

(3)
95%
0
2. class 1
class 2

X=/

X1
1 < X 2
2 < X 3
3 < X

1
0.8
0.6
0

3.
1
4.= 1,000 /

1.

6 150%0

250%1

1 2.

1. =1
85

() 3
2. 2

3.

50%()

4.

5.

350%

1000
540

540 1

100
350 90

540/1000*100
54%50% 1

86

3501+100+903920
4.=
11
2= 500 /

87

98 11 30 0980072848

()

()
()

88

E-mail

.
.
. 7
. 10

89

1.
2. 10 6
3.
4.

5.
6.

7.
8.
()

100 101

90

 1

1. 100 1 1
2. 99 1 1
3. 99
5

()

-1

6
6

(
)

-2a

ASC-US
6 ASC-US (
6
4)

:1)
2) 3)HPV test

-2b

LSIL 6 LSIL (
6

6, 7)

-3a1

2
(High
(High HSIL)(
HSIL) 2
8-11,16,17)

-3a2

2
(High
(High HSIL)
HSIL) 2
( 8-11,16,17)

-3b1

2
2 ( 5,12, 15, 18)

91

-3b2

2
2 (5,12,15,18)

-4a

ASC-H ASC-H (
2 CIN2() 16) 2
CIN2 ( HSIL)
HSIL

-4b

HSIL HSIL (
2 CIN2() 8-10,) 2
CIN2 ( HSIL)
HSIL

-5

HSIL 6 HSIL AGC

AGC 6 (

5,15,8-12,16-18)

-a

CIN3 CIN3 2 CIN3 CIN3

2
04, 05, 07-10, 12

4Atypical Squamous Cells of Undetermined SignificanceASC-US

5Atypical Glandular CellsAC
6Mild dysplasia with koilocytesCIN1
7Mild dysplasia CIN1 without koilocytes
8Moderate dysplasia CIN2
9Severe dysplasia CIN3
10Carcinoma In Situ CISCIN311Squamous Cell Carcinoma (SCC)
12Adenocarcinoma
13Other malignant neoplasm
15Atypical Glandular Cells Favor Neoplasm
16Atypical Squamous Cells of Undetermined Significance cannot exclude HSIL (ASC-H)
17Dysplasia cannot exclude HSIL
18Endocervical Adenocarcinoma In Situ (AIS)

00Unremarkable cervical epithelium(no pathological change, no pathological diagnosis)

01Benign epithelial lesion(Benign tumor, Inflammatory & reactive changes)
02Mild dysplasia(Flat condylomaCIN1LSIL)
03 Moderate dysplasia (CIN 2,HSIL)

92

04Severe dysplasia (Carcinoma in situ; CIN 3, HSIL)

05Squamous cell carcinoma
06Atypical glandular hyperplasia and dysplasia
07Adenocarcinoma in situ
08Adenocarcinoma
09Adenosquamous carcinoma
10Carcinoma(NOS, or other specific type)
11 : Mesenchymal tumor, benign
12Mesenchymal tumor, malignant
13others
CIN3 CIN3 040507-1012

()

-1

0 2 2 0

-2

45 2 45
2

-a

2 2

0: Need Additional Imaging Evaluation

4: Suspicious AbnormalityBiopsy Should Be Considered
5: Highly Suggestive of MalignancyAppropriate Action Should Be Taken

()
93


-1

-2

-1

-2

-3

-4

-6

Adenoma
1

-7

-8

-9

-a

0.6cm

-b

-5

Adenoma

0.6cm

94

1. 0.6cm
2.
3.
(excellent)no or minimal solid stool and only clear fluid requiring suction

(adequate)collection of semi-solid debris that are cleared with washing/suction

complete despite poor prep

solid or semi-solid debris that cannot be cleared effectively but which
still permits intubation to caecum

(failed due to poor prep)solid debris that cannot be cleared effectively and prevents intubation to
caecum

4. 30
(minor)
procedure aborted
unplanned post-procedure medical consultation
unplanned hospital admission, or prolongation of hospital stay, for3
nights 3
(intermedial)
Hb drop of 2g/dl 2g/dl
transfusion
unplanned admission or prolongation for 4-10 nights
4-10
ITU admission for 1 nightITU 1
major
sugery
unplanned admission or prolongation for 10 nights
10
ITU admission 1 nightITU 1
fatal

()

-1

homogenous thick
leukoplakiaverrucous
hyperplasia 2

95

homogenous thick


-2

-3

WHO
dysplasia

-1a

leukoplakiaverrucous
hyperplasia

(basement membrane)
(

WHO
dysplasia
(

)

6

moderate dysplasia

12
2
moderate dysplasia

4

severe dysplasia

8
2
severe dysplasia

2 Verrucous hyperplasia without
dysplasia severe dysplasia

oral cancer

moderate dysplasia
6 1

-1b
moderate dysplasia
12 2

-2a
severe dysplasia 4
1

severe dysplasia 8
-2b
2

Verrucous hyperplasia
-1
without dysplasia
severe dysplasia oral
cancer 2

1.
2.-1
3.-1 Excisional biopsy section line free
4. ErythroplakiaErythroleukoplakia
Non-homogeneous
Leukoplakia
5. 1-11

()

-1

CIN2-3 CIN2-3

96

-2

6
CIN2-3 CIN2-3
6

-3

1
CIN2-3 CIN2-3
1

-4

CIN2-3 CIN2-3

-5

CIN2-3 50 CIN2-3 50
() (ECC)
()

(ECC)

-6

6
CIN2-3 CIN2-3
6

-7

6
CIN2-3 CIN2-3
6

-8

CIN2-3 CIN2-3

-1

CCRT 2 CCRT
2

-2

-3

97

-4

IV B FIGO 3 IV B FIGO
3

-6

365

365

-7

FIGO I-IV I-IV I-IV

:
Life-Table

1.
(a) (ECC)
(b)

(c) (ablative)()

(d) HSIL CIN IICIN III CIS

2.

()

-1

45 () 45 ()
3 x 3 x

-2

-1

tumor2.5

tumor2.5

10
10

98

-2A

I I

-2B

II II

-3

-4

10 10

Sentinel
node biopsy

-5

ER ER

-6

PR PR

-7

Her2 Her2

-8

-9

99

-10

-1

I-IV

:
Life-Table

()

-1

(Colon & Rectum) Colon & Rectum

x x
CT scan CT scan
MRI

-1

MRI

x
CT scan MRI

(Colon & Rectum) 6 Colon &

6 6 Rectum
6

-2

malignant polyp
6 malignant polyp
A.B.C.D. 6
A.B.C.D.
wide wide surgical resection
surgical resection
A.
A.

B.

B.

C.
100

D. 3

C.

D. 3

-3A

Colon
I-III I-III Colon
curative
resection

curative resection
(tissue proof)

-3B

(Colon)
I-III
curative
resection

curative resection

-4

-5

I-III Colon

(tissue proof)

(Colon & Rectum)I-III

Colon & Rectum

I-III
curative resection
(
polypectomy )

I-III
I-III
(Colon & Rectum)
Colon & Rectum

(
)

101

-6

(Colon & Rectum) Colon & Rectum

TN

TN

-7

I-III

(Colon & Rectum) 12

12

-8

(Colon) III

I-III Colon &

Rectum
Polyp wide excision

6 Colon

III
(
)

-9

IIIII 6 IIIII
(Rectum)6 CCRT Rectum

:
CCRT

-10

IIIII CCRT IIIII

CCRT(Rectum) 16
CCRT
CCRT 16

Rectum

-1

I-III (Colon &

I-III Colon &
Rectum) 6 Rectum
6

-2A

I-III (Colon &

2 I-III Colon &
Rectum) Rectum
2

-2B

I-III (Colon &

Rectum)
3

I-III Colon &

Rectum
3

-3

polypectomy polypectomy polypectomy

polypectomy 12
12

102


-4

Colon & Rectum

I-V
:
Life-Table

()
ICD-O-3 C00-C06

-1

margin
status

-2

ECSECS

-3

margin status

-4

-5

-6

6 6

-7

(ECS
(ECSmargin margin )
)

-8

30 30

-1A

1 1
4
4

103

-1B

2 2
4
4

-2

3-5 3-5 5
2
2

-3

I-IV A

:
Life-Table

()

-1

(

1~2cm
>2cm

>2cm>200 ng/ml)
MRCT

-1

BCLC 0+A

TA(C)E

:
1.

2.

RFAPMCT
PEIPAT
3.TA(C)E

curative

2
104


-1

TAE echo, CT, MRI

2
echo, CT, MRI

curative TAE

AFP>20ng/ml curative

-2

TAE 2 AFP>20ng/ml
curative TAE AFP

2 AFP
curative TAE

-1

curative 1
TAE echo, CT, MRI 3
1 echo,
CT, MRI 3

-2

AFP>20ng/ml curative

TAE 1 curative TAE

curative TAE AFP 3
1 AFP 3

-1

BCLC 0, A,
B, C, D
:
Life-Table

-2A BCLC 0

:
Life-Table

-2B BCLC A

:
Life-Table

105

curative TAE

1
1

AFP>20ng/ml
1
1

-2C BCLC B

:
Life-Table

-2D BCLC C

:
Life-Table

-2E BCLC D

:
Life-Table

R/T Palliative R/T

curative
1
2(RFA) (PMCT) (PEI)
(PAT))
(TA(C)E)
(HAI) radiotherapy

(TA(C)E) RFA RFA;

()

-1

-2

I-III I-III

-3

(
pulmonary function
test)
106

-4A

I-III I - III

-4B

I-III I - III

-1

I- I-

-2

I- I-

-3

I-IIIA I-IIIA

2 2 2 Levels of
2 Levels of N2 N2

-4

I-
I-

-5

I- I-

( (
target therapyCCRT target
palliative care therapyCCRT
)

palliative care
)

107

-6

A A

(lobectomy)
(pneumonectomy

-7

A A
(wedge)

(segmentectomy)

-8

A A

3 () 3 3 Levels of

N2()

-9

A
A

-10

A A

-11

IIIB ECOG
01 2 IIIB

N3

-1

I
IIIII AIII BIV

:
Life-Table

108

()EC junction

-1
EC

junction

-2
EC junction EC
junction

X
X
MRI
EC junction
(Clinical TNM staging) MRI

EC
junction
Clinical TNM staging

-3

mucosectomy mucosectomy

endoscopic
submucosa endoscopic
dissection, ESD submucosa dissection,
endoscopic ESDEC
ultrasound, EUS junction

endoscopic
ultrasound, EUS

-1
I~ IIIB I~ IIIB
EC junction EC
6 junction

-2
I~ IIIB I~ IIIB
EC junction EC
junction
()

-3
M1 M1
109

EC junction

EC junction

mucosectomy
endoscopic
submucosa
dissection,
ESDEC
junction

I~ IIIB
EC
junction

I~ IIIB
EC
junction

M1

EC junction EC

junction

-4
D2 D2
dissectionEC dissection
junction EC junction
15
15

-1
30 30

EC junction

-2
R0/R1
resectionEC R0/R1 resection
junction 6 EC
junction
6

-3

EC junction EC junction
1 1

-4
R0 EC R0
junction 1 EC junction
X 1
X

-5

R0 R0
EC junction
135 EC junction

135

-6

EC
junction EC junction
1
1

()
110

EC junction

D2
dissection
EC junction

EC junction

R0/R1
resection
EC junction

EC junction

R0
EC junction

R0

EC junction

EC junction


-1

-2

-3

-4

-1

-2

-3

(
)
PET CT
Chest CT PET CT
magnetic Chest CT
resonance imaging, MRI magnetic
Clinical resonance imaging, MRI
TNM staging

Clinical
TNM
staging

/
/ cervix, cervix,
upper and/or middle thorax upper and/or middle
thorax
bronchoscopy

bronchoscopy

mucosectomy mucosectomy
endoscopic submucosa endoscopic
dissection, ESD submucosa dissection,
endoscopic ESD
ultrasound, EUS

endoscopic
ultrasound, EUS

(concurrent
chemo
(concurrent
radiotherapy, CCRT) chemo radiotherapy,
CCRT)

resectable
resectable
induction, neoadjuvant concurrent
concurrent chemo radiotherapy,
chemoradiotherapy, CCRT CCRT

111

/
cervix, upper
and/or middle thorax

mucosectomy
endoscopic
submucosa
dissection,
ESD

(concurrent chemo
radiotherapy, CCRT)

resectable

-4

resectable

concurrent
chemo
radiotherapy, CCRT

resectable

concurrent
chemo
radiotherapy, CCRT

-5

resectable

concurrent
chemo
radiotherapy, CCRT

-6

resectable

microresidualR1
R2

concurrent chemo
radiotherapy, CCRT

-7

unresectable

concurrent
chemo
radiotherapy, CCRT

-8

unresectable

concurrent
chemo
radiotherapy, CCRT

resectable

concurrent chemo
radiotherapy, CCRT

resectable

concurrent chemo
radiotherapy, CCRT

resectable

concurrent chemo
radiotherapy, CCRT

resectable

micro
residualR1

R2

adjuvant
concurrent chemo
radiotherapy, CCRT

unresectable

concurrent
chemo radiotherapy,
CCRT

unresectable

concurrent
chemo radiotherapy,
112

resectable

resectable

resectable

resectable

microresidual
R1
R2

unresectable

unresectable

-9

M1

palliative
concurrent chemo
radiotherapy, CCRT

-10

resectable

R0

-11

resectable
induction
concurrent
chemo

radiotherapy, CCRT

15

-12

resectable
concurrent chemo
radiotherapy, CCRT

-1

30

-2

-3

135

CCRT

palliative
concurrent
chemo radiotherapy,
CCRT

resectable

R0

resectable

induction
concurrent
chemo
radiotherapy, CCRT

15

resectable

concurrent chemo
radiotherapy, CCRT

30

113

resectable

(induction
concurrent
chemo radiotherapy,
CCRT)

resectable

induction
concurrent
chemo

radiotherapy, CCRT)

resectable

concurrent chemo
radiotherapy, CCRT)

-4

135

-5

135

(1)
(2)
(3) concurrent
chemoradiotherapy, CCRT
12

-6

135

135

135

(1)(2)
(3)
concurrent chemo
radiotherapy, CCRT
12

() ()

-1
-2
-3

PSA

10

PSA

10

(Gleason score)

-4

(Gleason score)

-5

-1

-2

114

T1-T2a PSA
10ng/ml
(Gleason score)
2-6

-3

1.8-2.2Gy
72Gy

-4

-5

-1

T2 6
PSA

-2
-3
-4
-5

5 10

5 10

5 10
(biochemical failure rate)

1.8-2.2Gy
72Gy

6
PSA 0.2 ng/ml

T2

(life-table) Kaplan-Meier
(life-table) Kaplan-Meier
(life-table) Kaplan-Meier
(life-table) Kaplan-Meier

()

-1

-2

-3

-4
-1

(TURBT)
(transurethral resection of bladder

tumor, TURBT)
(muscularis propria )
(muscularis propria )

(low / high grade)

(T2-T4aN0M0)

115

(TURBT)

(cystectomy)

(partial
cystectomy)

CIS PUNLMP

(T2-T4aN0M0)

-2

-3

-1

-2

-3

-4
-5

(radical
cystectomy)

T3
T3

(radical cystectomy)

T3

(radical 5
(radical cystectomy)
cystectomy)

(T2, T3)
(T2,T3)
5
(T2, T3)

(T2,T3)

(transurethral
(Bacillus (Bacillus Calmette-Gurin,
resection of bladder
Calmette-Gurin, BCG)
BCG)
tumor, TURBT)

5
(life-table) Kaplan-Meier

5 (life-table) Kaplan-Meier

116

()

()

()

()

()

()

()

()

()

()()

117

 3-1

fellow

3-2
1.
1
2
3
4
2.
3.
4.
1

powder free

2spill kits 3.6.1

118

1. 1

(1) 1 1 (
) 9
(2) 1
() 9
(3) 1
() 9
2.
(1) ()

(2) ()

3.
(1) ()

(2) ()

4.
8

5.
6.
(1)

(2)

a.

119

b.
(3)

7.
(1)

(2)

(3)

a.

b.

(4)
8.
()
a.

()

b.
()

c.

d.
9.
02-231127502311275323112760
02-23119100 86121534
02-23117300
10043 102 7
medical.doh@infoexplorer.com.tw
service.pfp@gmail.com
https://pfp.bhp.doh.gov.tw

120

A. B.

C.

D.

E.

(10 )

IP

IP

E-mail

1.10043
102 7
2.
3.
4.
5.

121

()

)100

101

10043
102 7

122

100 101

1.

3
2.
3.
4.
10043 102 7
123

Potentially Malignant DisordersPMD

Homogenous thin leukoplakia

1.Erythroplakia
2.Leukoplakia
-- Homogenous thick leukoplakia
-- Non-homogenous leukoplakia
(granular/verruciform/nodular leukoplakia or
erythroleukoplakia)
3.Verrucous hyperplasia

Erosive type

Oral lichen planus

Non-erosive type

/
1. 3-6 1
2. PMD PMD

Oral submucous fibrosisOSF

124

PMD

Severe dysplasia (SIN3, atypical

hyperplasia)

1.

photodynamic therapy
2.

1.Moderate dysplasia (SIN2)

2.mild dysplasia (SIN1,
basal/parabasal cell hyperplasia)
3.lichenoid dysplasia

Verrucous hyperplasia without

dysplasia
Other non-dysplasic lesions
Epithelial hyperplasia
acanthosis, squamous cell
hyperplasiaor hyperkeratosis

Verrucous hyperplasiawith dysplasia

125

126